Correction Notice: Impact of T-cell Receptor Status on Mutational Landscape and Outcome in T-ALL

DOI: https://doi.org/10.1097/HS9.0000000000000980

2023-10-04

HemaSphere

Abstract:[This corrects the article DOI: 10.1097/HS9.0000000000000871.].

What problem does this paper attempt to address?

Author Correction: Targeted Inhibition of STAT/TET1 Axis As a Therapeutic Strategy for Acute Myeloid Leukemia

Xi Jiang,Chao Hu,Kyle Ferchen,Ji Nie,Xiaolong Cui,Chih-Hong Chen,Liting Cheng,Zhixiang Zuo,William Seibel,Chunjiang He,Yixuan Tang,Jennifer R. Skibbe,Mark Wunderlich,William C. Reinhold,Lei Dong,Chao Shen,Stephen Arnovitz,Bryan Ulrich,Jiuwei Lu,Hengyou Weng,Rui Su,Huilin Huang,Yungui Wang,Chenying Li,Xi Qin,James C. Mulloy,Yi Zheng,Jiajie Diao,Jie Jin,Chong Li,Paul P. Liu,Chuan He,Yuan Chen,Jianjun Chen

DOI: https://doi.org/10.1038/s41467-018-02947-0

IF: 16.6

2018-01-01

Nature Communications

Abstract:The original version of this Article contained an error in the spelling of the author James C. Mulloy, which was incorrectly given as James Mulloy. This has now been corrected in both the PDF and HTML versions of the Article.
Corrigendum: CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth

Ru Zhou,Mahboubeh Yazdanifar,Lopamudra Das Roy,Lynsey M. Whilding,Artemis Gavrill,John Maher,Pinku Mukherjee

DOI: https://doi.org/10.3389/fimmu.2020.628776

IF: 7.3

2020-12-07

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2019.01149.].

immunology
Correction Notice: Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use

DOI: https://doi.org/10.1097/HS9.0000000000000987

2023-10-31

HemaSphere

Abstract:[This corrects the article DOI: 10.1097/HS9.0000000000000907.].
Corrigendum: Tumor-Associated Macrophages in Tumor Immunity

Yueyun Pan,Yinda Yu,Xiaojian Wang,Ting Zhang

DOI: https://doi.org/10.3389/fimmu.2021.775758

IF: 7.3

2021-01-01

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2020.583084.].
Correction to "Single-cell RNA sequencing of pediatric Hodgkin lymphoma to study the inhibition of T cell subtypes"

DOI: https://doi.org/10.1002/hem3.70023

2024-10-07

HemaSphere

Abstract:[This corrects the article DOI: 10.1002/hem3.149.].
Correction: Corrigendum: The transcriptional coactivator TAZ regulates reciprocal differentiation of T H 17 cells and T reg cells

Hao Zhao

DOI: https://doi.org/10.1038/ni1117-1270c

IF: 30.5

2017-01-01

Nature Immunology

Abstract:Nat. Immunol. 18, 800–812 (2017); published online 15 May 2017; corrected after print 20 July 2017 In the version of this article initially published, the description of Figure 1d,e in the first subsection of Results was incorrect; “...(Lck-Cre): Tazfl/flLck-Cre mice) immunized with KLH exhibited a larger TH17 population and fewer Treg cells than that of their Tazfl/fl littermates.
Erratum: Sun C, Tian X, Lee YS, et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood. 2015;126(19):2213-2219

DOI: https://doi.org/10.1182/blood-2016-06-725010

IF: 20.3

2016-08-18

Blood

Abstract:[This corrects the article DOI: 10.1182/blood-2015-04-639203.].
Corrigendum: Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring

Águeda Molinos-Quintana,Anna Alonso-Saladrigues,Blanca Herrero,Teresa Caballero-Velázquez,Víctor Galán-Gómez,Melissa Panesso,Montserrat Torrebadell,Javier Delgado-Serrano,Concepción Pérez de Soto,Anna Faura,Berta González-Martínez,Ana Castillo-Robleda,Cristina Diaz-de-Heredia,Antonio Pérez-Martínez,José María Pérez-Hurtado,Susana Rives,José Antonio Pérez-Simón

DOI: https://doi.org/10.3389/fimmu.2024.1373852

IF: 7.3

2024-02-07

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2023.1280580.].

immunology
Corrigendum: Follicular lymphoma regulatory T-cell origin and function

Stéphane Rodriguez,Mehdi Alizadeh,Claire Lamaison,Alexis Saintamand,Céline Monvoisin,Rachel Jean,Laurent Deleurme,Jose Ignacio Martin-Subero,Céline Pangault,Michel Cogné,Patricia Amé-Thomas,Karin Tarte

DOI: https://doi.org/10.3389/fimmu.2024.1472373

2024-08-15

Abstract:[This corrects the article DOI: 10.3389/fimmu.2024.1391404.].
Erratum: Targeting Telomere Dynamics as an Effective Approach for the Development of Cancer Therapeutics [Corrigendum]

DOI: https://doi.org/10.2147/IJN.S500182

2024-10-14

Abstract:[This corrects the article DOI: 10.2147/IJN.S448556.].
Corrigendum: Immune Tolerance Induced by Hematopoietic Stem Cell Infusion after HLA Identical Sibling Kidney Transplantation

Hongfeng Huang,Qixia Shen,Jingyi Zhou,Xiuyan Yang,Qiuqin Cai,Jia Shen,Shi Feng,Wenqing Xie,Hong Jiang,Jianghua Chen

DOI: https://doi.org/10.3389/fimmu.2022.1052676

IF: 7.3

2022-01-01

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2022.995243.].
Erratum: Schwartz CL, Constine LS, Villaluna D, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood. 2009;114(10):2051-2059

DOI: https://doi.org/10.1182/blood-2016-06-723056

IF: 20.3

2016-07-28

Blood

Abstract:[This corrects the article DOI: 10.1182/blood-2008-10-184143.].
Erratum: Veenstra RG, Flynn R, Kreymborg K, et al. B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality. Blood. 2015;125(21):3335-3346

DOI: https://doi.org/10.1182/blood-2016-04-711242

IF: 20.3

2016-06-16

Blood

Abstract:[This corrects the article DOI: 10.1182/blood-2014-09-603357.].
Erratum: CD8 T cell function and cross-reactivity explored by stepwise increased peptide-HLA versus TCR affinity

DOI: https://doi.org/10.3389/fimmu.2023.1178295

IF: 7.3

2023-03-14

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2022.973986.].

immunology
Erratum to maintaining excellent outcomes: the impact of age cutoff reclassification on reduced therapy for neuroblastoma patients

Editorial Office

DOI: https://doi.org/10.21037/tp-2024-02

2024-09-02

Translational Pediatrics

Abstract:Editorial Office Translational Pediatrics Submitted Jul 15, 2024. Accepted for publication Jul 25, 2024. Published online Aug 28, 2024. doi: 10.21037/tp-2024-02 Erratum to: Transl Pediatr 2023;12:1926-30. The article (1) entitled "Maintaining excellent outcomes: the impact of age cutoff reclassification on reduced therapy for neuroblastoma patients" ( Transl Pediatr 2023;12:1926-30. doi: 10.21037/tp-23-391) unfortunately contained some mistakes in the main text on page 1929. In paragraph 14, the "event-free-survival" should be "overall survival". The OS should be EFS. The data "91%±4.4% (≤2006) versus 88%±4.3% (>2006)" should be "89%±5.1% (≤2006) versus 87%±4.6% (>2006)". The corrected content is presented as below: Survival analyses revealed that there were no significant differences in overall survival after the reassignment being 89%±5.1% (≤2006) versus 94%±3.2% (>2006). The similar trend was observed for EFS showing 89%±5.1% (≤2006) versus 87%±4.6% (>2006). The small increase in OS observed in the group of patients treated >2006 could be due to the better response of a small subset of patients that relapse. The authors apologize for these errors and state that these errors do not change the scientific conclusions of the article in any way. Click here to view the updated version of the article. Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

pediatrics
Erratum: Genetic Predisposition to Numerous Large Ulcerating Basal Cell Carcinomas and Response to Immune Therapy: Erratum

DOI: https://doi.org/10.1097/JD9.0000000000000184

Abstract:[This corrects the article DOI: 10.1097/JD9.0000000000000170.].
Corrigendum: Alpha Thalassemia/Intellectual Disability X-Linked Deficiency Sensitizes Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors

Tao Hou,Shun Jiang,Yapeng Wang,Yangchun Xie,Haixia Zhang,Yeqian Feng,Fang Ma,Jin’an Ma,Xianling Liu,Chunhong Hu

DOI: https://doi.org/10.3389/fonc.2021.705406

IF: 4.7

2021-06-02

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2020.608300.].

oncology
Correction: Tumor Driven by Gain-of-function HER2 H878Y Mutant is Highly Sensitive to HER2 Inhibitor.

Zexi Hu,Yong Hu,Xicheng Liu,Rongwen Xi,Aiqun Zhang,Deruo Liu,Qiang Xie,Liang Chen

DOI: https://doi.org/10.18632/oncotarget.26252

2018-01-01

Oncotarget

Abstract:[This corrects the article DOI: 10.18632/oncotarget.5221.].
Erratum: Wang L, Man N, Sun X-J, et al. Regulation of AKT signaling by Id1 controls t(8;21) leukemia initiation and progression. Blood. 2015;126(5):640-650

DOI: https://doi.org/10.1182/blood-2016-03-703744

IF: 20.3

2016-04-14

Blood

Abstract:[This corrects the article DOI: 10.1182/blood-2015-03-635532.].
Erratum: Approaching hemophagocytic lymphohistiocytosis

Frontiers Production Office

DOI: https://doi.org/10.3389/fimmu.2024.1369687

IF: 7.3

2024-01-22

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2023.1210041.].

immunology

Correction Notice: Impact of T-cell Receptor Status on Mutational Landscape and Outcome in T-ALL

Author Correction: Targeted Inhibition of STAT/TET1 Axis As a Therapeutic Strategy for Acute Myeloid Leukemia

Corrigendum: CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth

Correction Notice: Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use

Corrigendum: Tumor-Associated Macrophages in Tumor Immunity

Correction to "Single-cell RNA sequencing of pediatric Hodgkin lymphoma to study the inhibition of T cell subtypes"

Correction: Corrigendum: The transcriptional coactivator TAZ regulates reciprocal differentiation of T H 17 cells and T reg cells

Erratum: Sun C, Tian X, Lee YS, et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood. 2015;126(19):2213-2219

Corrigendum: Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring

Corrigendum: Follicular lymphoma regulatory T-cell origin and function

Erratum: Targeting Telomere Dynamics as an Effective Approach for the Development of Cancer Therapeutics [Corrigendum]

Corrigendum: Immune Tolerance Induced by Hematopoietic Stem Cell Infusion after HLA Identical Sibling Kidney Transplantation

Erratum: Schwartz CL, Constine LS, Villaluna D, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood. 2009;114(10):2051-2059

Erratum: Veenstra RG, Flynn R, Kreymborg K, et al. B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality. Blood. 2015;125(21):3335-3346

Erratum: CD8 T cell function and cross-reactivity explored by stepwise increased peptide-HLA versus TCR affinity

Erratum to maintaining excellent outcomes: the impact of age cutoff reclassification on reduced therapy for neuroblastoma patients

Erratum: Genetic Predisposition to Numerous Large Ulcerating Basal Cell Carcinomas and Response to Immune Therapy: Erratum

Corrigendum: Alpha Thalassemia/Intellectual Disability X-Linked Deficiency Sensitizes Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors

Correction: Tumor Driven by Gain-of-function HER2 H878Y Mutant is Highly Sensitive to HER2 Inhibitor.

Erratum: Wang L, Man N, Sun X-J, et al. Regulation of AKT signaling by Id1 controls t(8;21) leukemia initiation and progression. Blood. 2015;126(5):640-650

Erratum: Approaching hemophagocytic lymphohistiocytosis